Interview with Howard Balloch, President, The Balloch Group
What initially attracted you to China and what kept you here over the years? I initially became interested in China during university where I studied the country and wrote a…
Yangtze River Pharmaceutical Group is a Chinese multinational pharmaceutical corporation headquartered in Taizhou, Jiangsu Province in the People’s Republic of China, and with its research headquarters in Shanghai. It is one of the Asia’s largest pharmaceutical companies by revenues, and was listed in 2014 as being China’s second largest pharmaceutical manufacturer, and leading company for technological and entrepreneurial innovation.
Founded in 1971, the Yangtze River Pharmaceutical Group started as a local firm providing drugstores and hospitals with vitamin supplements and pain medication. For much of its early existence, profit margins were low due to the YRPG’s inability to expand a fledgeling sales network past a local level. This changed at the end of the 20th century when sweeping economic and medical reforms placed an ever-increasing demand on quality drug production.[5] Located in a prime location between the major cities of Shanghai, Suzhou, and Hangzhou, the YRPG quickly expanded its business profile. The group has experienced significant growth in the past decade, having quadrupled their net income between 2003-2010.[1] In the fiscal year 2014, board shareholders received a record 560% return on investment, and company assets rapidly expanded.[1] The company also hosts 22 subsidiary firms across Asia and has exploratory ventures in Europe, Canada, and the United States.
What initially attracted you to China and what kept you here over the years? I initially became interested in China during university where I studied the country and wrote a…
You have had significant experience at GSK and Pfizer, and also at Frontage Labs doing more entrepreneurial work. What ultimately brought you to Covance? I worked in Big Pharma for…
Could you please give us a brief introduction on CMBA? First and most obviously for new arrivals to our office, since 2011 we have changed locations, making it more convenient…
Your background before joining Beaufour Ipsen is quite unique among country managers of pharmaceutical companies: working many years in academia and focused very much on Asian studies. What brought you…
Your business is very much relationship based here in China. You’ve now established a number of relationships with institutes, universities and companies, but I can imagine that breaking into this…
SinoGenoMax was founded in 1998 with the purpose of participating in the Human Genome Project. Could you give us an overview of the company’s activities since then and the transformation…
You have a long experience in the Chinese pharmaceutical market, and in particular you saw it evolve tremendously over the last 10 years. From a management perspective, would you say…
We found a Capital Markets Day presentation from Novo Nordisk that talked about the “rule of halves” – that of all people with diabetes, 50% of diagnosed, and of those…
You completed your higher education in the US and worked there for a period afterwards; what caused you to move back to China and start this company? A lot of…
Liam Condon, Managing Director of Bayer Healthcare China discusses the government’s recent announcements regarding its much-anticipated healthcare reform plan, the future benefits of investing in rural healthcare, and the company’s…
In the last decade the medical device sector has undergone a lot of change; China has become a net importer to a net exporter of these devices. What is your…
You started the Chinese operations and have been working in the country for many years but recently moved up to running all operations in Asia Pacific. Are you still closely…
See our Cookie Privacy Policy Here